Price Alert

Immunocore (IMCR)

NASDAQ: IMCR · Real-Time Price · USD

35.26

-0.01 (-0.03%)

At close: Sep 04, 2025, 11:17 AM

-0.03% (1D)

Bid	25.15
Market Cap	1.78B
Revenue (ttm)	356.14M
Net Income (ttm)	-20.31M
EPS (ttm)	-0.41
PE Ratio (ttm)	-85.99
Forward PE	-33.26
Analyst	Buy

Ask	44.42
Volume	138,762
Avg. Volume (20D)	339,659
Open	35.54
Previous Close	35.27
Day's Range	34.61 - 35.54
52-Week Range	23.15 - 39.33
Beta	0.78

About IMCR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol IMCR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for IMCR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Immunocore is scheduled to release its earnings on Nov 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+6.63%

Immunocore Holdings shares are trading higher afte... Unlock content with Pro Subscription

News

3 weeks ago · seekingalpha.com

Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript

Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants & - Corporate Participant Bahija Jallal - CEO & Executive Director Clayton Robert...

3 weeks ago · fool.com

Immunocore (IMCR) Q2 Revenue Jumps 30%

Immunocore Plc (IMCR 0.06%), a biotechnology company specializing in T cell receptor therapies, reported its second quarter 2025 results on August 7, 2025. The main headline was a solid revenue increa...

3 weeks ago · zacks.com

Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Immunocore (IMCR) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare...

1 month ago · zacks.com

Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

The consensus price target hints at a 72.3% upside potential for Immunocore (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima...

2 months ago · zacks.com

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli...